The etiology and pathogenesis of type 1 diabetes - A personal, non-systematic review of possible causes, and interventions
- PMID: 36093076
- PMCID: PMC9452747
- DOI: 10.3389/fendo.2022.876470
The etiology and pathogenesis of type 1 diabetes - A personal, non-systematic review of possible causes, and interventions
Abstract
In this review after a lifelong research career, my personal opinion on the development of type 1 diabetes (T1D) from its very start to clinical manifestation will be described. T1D is a disease of an increased intestinal permeability and a reduced pancreas volume. I am convinced that virus might be the initiator and that this virus could persist on strategically significant locations. Furthermore, intake of gluten is important both in foetal life and at later ages. Disturbances in sphingolipid metabolism may also be of crucial importance. During certain stages of T1D, T cells take over resulting in the ultimate destruction of beta cells, which manifests T1D as an autoimmune disease. Several preventive and early treatment strategies are mentioned. All together this review has more new theories than usually, and it might also be more speculative than ordinarily. But without new ideas and theories advancement is difficult, even though everything might not hold true during the continuous discovery of the etiology and pathogenesis of T1D.
Keywords: beta-cell activity; etiology; gluten; pathogenesis; sphingolipids; sulfatide; type 1 diabetes; virus.
Copyright © 2022 Buschard.
Conflict of interest statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Is it time to challenge the established theories surrounding type 1 diabetes?Acta Paediatr. 2014 Feb;103(2):120-3. doi: 10.1111/apa.12452. Acta Paediatr. 2014. PMID: 24344989
-
Chemokines as Drivers of the Autoimmune Destruction in Type 1 Diabetes: Opportunity for Therapeutic Intervention in Consideration of an Optimal Treatment Schedule.Front Endocrinol (Lausanne). 2020 Oct 19;11:591083. doi: 10.3389/fendo.2020.591083. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33193102 Free PMC article. Review.
-
New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes.Int J Mol Sci. 2019 Sep 26;20(19):4789. doi: 10.3390/ijms20194789. Int J Mol Sci. 2019. PMID: 31561568 Free PMC article. Review.
-
What causes type 1 diabetes? Lessons from animal models.APMIS Suppl. 2011 Jul;(132):1-19. doi: 10.1111/j.1600-0463.2011.02765.x. APMIS Suppl. 2011. PMID: 21615797 Review.
-
The C24:0 Sulfatide Isoform as an Important Molecule in Type 1 Diabetes.Front Biosci (Landmark Ed). 2022 Dec 27;27(12):331. doi: 10.31083/j.fbl2712331. Front Biosci (Landmark Ed). 2022. PMID: 36624946 Review.
Cited by
-
SARS-CoV-2 Positive Serology and Islet Autoantibodies in Newly Diagnosed Pediatric Cases of Type 1 Diabetes Mellitus: A Single-Center Cohort Study.Int J Mol Sci. 2023 May 17;24(10):8885. doi: 10.3390/ijms24108885. Int J Mol Sci. 2023. PMID: 37240231 Free PMC article.
-
Applications of Genome-Editing Technologies for Type 1 Diabetes.Int J Mol Sci. 2023 Dec 26;25(1):344. doi: 10.3390/ijms25010344. Int J Mol Sci. 2023. PMID: 38203514 Free PMC article. Review.
-
Challenges and opportunities in the islet transplantation microenvironment: a comprehensive summary of inflammatory cytokine, immune cells, and vascular endothelial cells.Front Immunol. 2023 Dec 4;14:1293762. doi: 10.3389/fimmu.2023.1293762. eCollection 2023. Front Immunol. 2023. PMID: 38111575 Free PMC article. Review.
-
Melatonin ameliorates high glucose-induced autophagy in Schwann cells.Int J Biochem Mol Biol. 2023 Jun 15;14(3):25-31. eCollection 2023. Int J Biochem Mol Biol. 2023. PMID: 37456910 Free PMC article.
-
Early Onset of Type 1 Diabetes in Kuwait: Distinct Clinical, Metabolic, and Immunological Characteristics.Med Princ Pract. 2024;33(6):555-561. doi: 10.1159/000540705. Epub 2024 Aug 2. Med Princ Pract. 2024. PMID: 39097968 Free PMC article.
References
-
- Xia CQ, Liu YT, Guan QB, Clare-Salzler M. Anti-lymphocyte antibody-based immunotherapy in type 1 diabetes. Chin Med J (Engl) (2013) 126(5):957–64. - PubMed
-
- Barcenilla H, Pihl M, Wahlberg J, Ludvigsson J, Casas R. Intralymphatic GAD-alum injection modulates b cell response and induces follicular helper T cells and PD-1+ CD8+ T cells in patients with recent-onset type 1 diabetes. Front Immunol (2021) 12:797172. doi: 10.3389/fimmu.2021.797172 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical